Cronos Group Inc. today announced that it has entered into a subscription agreement with Altria Group, Inc. pursuant to which Altria has agreed to make an approximately C$2.4 billion equity investment in Cronos Group on a private placement basis in exchange for common shares in the capital of the Company. Altria will also receive Warrants of Cronos Group, that if fully exercised, would provide the Company with an additional approximately C$1.4 billion of proceeds. The Shares issuable to Altria pursuant to the Subscription Agreement will result in Altria holding an approximately 45% ownership interest in Cronos Group (calculated on a non-diluted basis), exercise of the Warrants would result in incremental ownership of 10% for a total potential ownership position of 55%. This strategic partnership provides Cronos Group with additional financial resources, product development and commercialization capabilities, and deep regulatory expertise to better position the Company to compete, scale and lead the rapidly growing global cannabis industry.

Cronos Group Inc. today confirmed that it is engaged in discussions concerning a potential investment by Altria Group Inc. in Cronos Group. No agreement has been reached with respect to any such transaction and there can be no assurance such discussions will lead to an investment or other transaction involving the companies.

“We are encouraged with our third quarter results, which reflect the meaningful progress we are making on our strategic initiatives. In the quarter, we announced a number of landmark partnerships to expand our reach beyond the flower and beyond Canada and launched our second differentiated recreational cannabis brand,” said Mike Gorenstein, CEO of Cronos Group.

Cronos Group, a geographically diversified and vertically integrated cannabis group, will announce its financial results and hold its Third Quarter 2018 Earnings Conference Call on Tuesday, November 13, 2018 at 8:30 a.m. EDT. Senior management will be available for questions from the investment community after prepared remarks.

Today, Canada became the first G7 country and the second country in the world to legalize cannabis sales for adult recreational use.

Cronos Group Inc. Partners with Technion Research & Development Foundation for Cannabinoid-Based Skin Care Treatments.

The study is funded in part by Peace Naturals Project Inc., a licensed producer of medical cannabis that is wholly owned by Cronos Group. The study will be led by physicians practicing within the Canabo Medical Clinic network, which is wholly owned by Aleafia.

Spinach™ is focused on offering Farm-To-Bowl™ products that bring friends together and make experiences more enjoyable. Spinach™ has selected some of the most popular strains from Cronos Group’s genetic library because when you’re having fun, you should never have to worry about the quality of your Spinach™. Harmful additives don’t have a place in good Spinach™, which is why quality control is the only think we take seriously. More information on how to Get-Your-Greens™ can be found at www.spinachcannabis.com. Warning: Spinach™ may be a gateway to pizza

Leading Companies from Emerging Industries Join Forces to Efficiently Produce High-Purity Cannabinoids at Scale.
Today, Cronos Group Inc. and Ginkgo Bioworks Inc. announced a landmark partnership to produce cultured cannabinoids. Using its platform technology for organism design and development, Ginkgo will complement Cronos Group’s technologies for producing a full spectrum of cannabinoids. As part of this unprecedented deal, Cronos Group has agreed to issue a specific number of common shares in tranches subject to Ginkgo’s achievement of certain production milestones.

Cronos Group Inc., is pleased to announce that it has entered into a joint venture agreement with an affiliate of Agroidea SAS (“AGI”), Colombia’s leading agricultural services provider with over 30 years of research, development and production operations. This partnership establishes a newly formed entity, NatuEra S.à r.l. (“NatuEra”), in Colombia that will develop, cultivate, manufacture and export cannabis-based medicinal and consumer products for the Latin American and global markets.

Cronos Group has secured listings and signed binding master supply agreements with both the Ontario Cannabis Retail Corporation and the BC Liquor Distribution Branch. In combination, these provinces encompass over 50% of the Canadian population and hence the potential customer base which the Company is prepared to serve.

“This year and subsequently, this quarter is about setting the stage and establishing Cronos Group’s strategy for future growth,” said Mike Gorenstein, CEO of Cronos Group. “Cronos Group delivered encouraging results across the Company in the second quarter with sales growing among all of our products and channels, impressive improvements in cultivation yields since the start of the year, and continued business development success in penetrating new markets and establishing new partnerships for expansion.”

Cronos Group Inc., is pleased to announce that it has entered into a supply agreement with one of the largest cannabis companies in the world by revenue in the first quarter of 2018, Cura Select Canada, Ltd. Cura is on a mission to be the leading provider of premium cannabis oil and hemp oil to the legal U.S. and international markets, and will enter the Canadian market to supply domestic and international channels.

Cronos Group Inc., is pleased to announce that it has entered into a joint venture partnership with a group of investors led by Bert Mucci (the “Greenhouse Partners”), one of Canada’s most sophisticated greenhouse operators and builders.

Cronos Group Inc., a geographically diversified and vertically integrated cannabis group, will announce its financial results and hold its Second Quarter 2018 Earnings Conference Call.

(“Cronos Group” or the “Company”), a geographically diversified and vertically integrated cannabis group, reports that at its Annual and Special Meeting of Shareholders on June 28, 2018 there were 658 shareholders voting in person and by proxy holding in total 92,611,201 common shares, representing 52.56% of the total number of common shares outstanding.

Cronos Group Inc., is pleased to announce that it has entered into a strategic distribution partnership with Delfarma Sp. Zo.o. Founded in 2004, Delfarma is a privately owned pharmaceutical wholesaler and was the first company in Poland to introduce international parallel import of medicinal products from European Economic Area countries.

(“Cronos Group” or the “Company”), is pleased to announce that Cronos Australia Pty Ltd. (“Cronos Australia”) has been granted a medicinal cannabis Manufacture License by the Australian Office of Drug Control.

Cronos Group Inc. will hold its 2018 Annual and Special Meeting of Shareholders on Thursday, June 28, 2018 at 9:30 a.m. at the offices of Blake, Cassels & Graydon LLP located at 199 Bay Street, Suite 4000, Commerce Court West, Toronto.

The Cronos Group Inc. is pleased to announce that trading of its common shares in Canada will be elevated from the TSX Venture Exchange (“TSX-V”) to the Toronto Stock Exchange (“TSX”).

The Cronos Group Inc. announced today it has appointed Jim Rudyk as lead director and has entered into an engagement agreement to retain Athena Advisors LLC (“Athena Advisors”) as its agency of record for investor relations and corporate communications.

Cronos Group Inc. today announced financial results for the first quarter ended March 31, 2018.

Cronos Group Inc. will release its financial results for the first quarter ended March 31, 2018 before the market opens on May 15, 2018.

Cronos Group Inc. today announced financial results for the fourth quarter and fiscal year ended December 31, 2017.
“We are building Cronos Group with a focus on the long-term and 2017 set the foundation for the explosive growth we have already started realizing in 2018,” said Mike Gorenstein,” CEO of Cronos Group.  “We are extremely proud of all that our team has accomplished and look forward to a year of rapid increases in sales, commencing distribution in new markets, further developing disruptive intellectual property and launching new iconic brands.”

    TORONTO, April 27, 2018 /CNW/ – Cronos Group Inc. (NASDAQ, TSX-V: CRON) ("Cronos Group" or the "Company") will release its financial results for the fourth quarter and fiscal year ended December 31, 2017 before the market opens on April 30, 2018. Conference Call...

Cronos Group is pleased to announce that it has closed its previously announced bought deal public offering. A total of 10,420,000 common shares of Cronos Group were sold at a price of $9.60 per Share for aggregate gross proceeds of approximately $100.0 million.

Cronos Group is pleased to announce that it has entered into an agreement with a syndicate of underwriters co-led by GMP Securities L.P. and BMO Capital Markets to sell 10,420,000 common shares (11,983,000 common shares if the over-allotment described below is exercised in full) of the Company, on a “bought deal” basis, at a price of $9.60 per common share, for gross proceeds of approximately $100.0 million (approximately $115.0 million if the over-allotment option is exercised in full).

With Canada on track to legalize adult use of cannabis, two of the world’s largest cannabis companies announced a first-of-its-kind cross border joint venture today that could bring America’s most recognized cannabis brand to Canadian consumers by year’s end.

Cronos Group Inc. is pleased to announce that the Company is changing its ticker on the TSX Venture Exchange from MJN to CRON. This change is effective immediately for trading commencing on Monday, March 5 and is being made to conform to the ticker symbol that was selected when Cronos Group became the first pure-play cannabis company to trade on the Nasdaq on February 27, 2018

Cronos Group Inc. (TSX-V: MJN) (OTC Nasdaq Int’l Designation: PRMCF) is pleased to announce that trading of its common shares in the United States will be elevated from the Nasdaq International Designation program to the Nasdaq Global Market. Cronos Group expects that its common shares will begin trading on Nasdaq on February 27, 2018 under the trading ticker symbol “CRON.” Cronos Group will retain its listing on the TSX Venture Exchange under the symbol “MJN.”

Cronos Australia is a 50/50 joint venture between the Group and NewSouthern Capital Pty Ltd, led by Mr. Rodney Cocks and Mr. Peter Righetti.  Cronos Australia will serve as the Group’s hub for Australia, New Zealand, and South East Asia, bolstering the Group’s import/export supply capabilities and distribution network.  Cronos Australia will leverage the Group’s intellectual property and iconic brands to deliver premium cannabinoid based products to Australasia.

Mr. Rudyk is currently the chief financial officer of Roots Corporation (“Roots”), a position he has held since January 2016. Mr. Rudyk is an experienced and proven financial executive with more than 25 years of financial and operational experience and a track record of supporting ambitious growth plans.

(“Cronos Group” or the “Company”) is pleased to announce that it has closed its previously announced bought deal public offering, including the full exercise of the over-allotment option. As such, a total of 5,257,143 common shares of Cronos Group (the “Shares”) were sold at a price of $8.75 per Share for aggregate gross proceeds of approximately $46.0 million (the “Offering”).

Cronos Group is pleased to announce that Peace Naturals Project Inc., a licensed producer wholly owned by the Company, has just obtained a Dealer’s License pursuant to the Controlled Drugs and Substances Act under Health Canada.

Cronos Group Inc. is pleased to announce that the Company has entered into a revised agreement with a syndicate of underwriters led by PI Financial Corp., to increase the size of its previously announced bought deal financing to approximately $40 million aggregate gross proceeds, representing 4,571,429 shares of the Company, at a price of $8.75 per Share.

Cronos Group Inc. is pleased to announce that it has entered into a letter of engagement with PI Financial Corp. as lead underwriter on behalf of a syndicate of underwriters under which the Underwriters have agreed to purchase for re-sale 3,428,572 common shares of the Company.

TORONTO, ON (December 27, 2017) – Cronos Group Inc. (TSX-V: MJN) (OTC – Nasdaq Int’l Designation: PRMCF) (“Cronos” or the “Company”) is pleased to announce that its first shipment to G. Pohl-Boskamp GmbH & Co. KG (“Pohl-Boskamp”) of Peace Naturals (“Peace”)...

Cronos Group today reported financial results for the third quarter ended September 30, 2017.  Financial results and the management discussion and analysis are available on the Company’s website and SEDAR (www.sedar.com).

Cronos Group will release its financial results for the third quarter ended September 30, 2017 before the market opens on November 29, 2017

Cronos is pleased to announce that its previously announced strategic joint venture with Kibbutz Gan Shmuel for the production, manufacture, and global distribution of medical cannabis, has been approved by the TSX Venture Exchange.

Cronos Group is pleased to announce that it has closed its previously announced bought deal public offering, including the full exercise of the over-allotment option.

Cronos is pleased to announce that it has entered into a letter of engagement with PI Financial Corp.

Cronos is pleased to announce that it has entered into a strategic distribution partnership with G. Pohl-Boskamp GmbH & Co. KG (“Pohl-Boskamp”)

“We are extremely fortunate to have investors that share our vision and are focused on the long term. Our strategic capital partners add intangible value that doesn’t show up on the balance sheet,” said Mike Gorenstein, CEO of Cronos.

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES TORONTO, Sept. 18, 2017 /CNW/ - Further to its press release on September 14, 2017, Cronos Group Inc. ("Cronos" or the "Company") (TSX Venture: MJN) (OTC – Nasdaq International...

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES TORONTO, Sept. 14, 2017 /CNW/ - Cronos Group Inc. ("Cronos" or the "Company") (TSX Venture: MJN) (OTC – Nasdaq International Designation: PRMCF) is pleased to announce that it...

TORONTO, Sept. 12, 2017 /CNW/ - Cronos Group Inc. (TSXV: MJN) (OTC: PRMCF) ("Cronos" or the "Company") is pleased to announce that it is the first cannabis company to be admitted into the Nasdaq International Designation program under the symbol OTC – Nasdaq...

TORONTO, Sept. 6, 2017 /CNW/ - Cronos Group Inc. (TSXV: MJN) (OTC: PRMCF) ("Cronos" or the "Company") is pleased to announce that the Company has entered into a strategic joint venture ("Cronos Israel") with Kibbutz Gan Shmuel ("Gan Shmuel") for the production,...

Cronos Group is pleased to announce that one of its wholly-owned licensed producers, Peace Naturals Project Inc. has entered into a supply agreement with Cannamedical Pharma GmbH.

Peace Naturals Project Inc. has successfully completed the Company’s first shipment of medical cannabis oil to the Cayman Islands. This marks the first time Cronos has exported an extract based product.

TORONTO, Aug. 28, 2017 /CNW/ - Cronos Group Inc. (TSXV:MJN) (OTC: PRMCF) ("Cronos" or the "Company") is pleased to report the financial results and accompanying management discussion and analysis for the quarter ending June 30, 2017; copies are available on the...

TORONTO, Aug. 24, 2017 /CNW/ – Cronos Group Inc. is announcing today that it has entered into a commitment letter for $40 million in debt financing with Romspen Investment Corporation (“Romspen”) to fund the continued construction of its 315,000 sq. ft. expansion (the “New Peace Facility”) previously outlined in the Company’s press release dated May 23, 2017.

TORONTO, May 30, 2017 /CNW/ - Cronos Group Inc. (TSX VENTURE: MJN) ("Cronos" or the "Company") is pleased to report the financial results and accompanying management discussion and analysis for the quarter ending March 31, 2017; copies are available on the Company's...

The expansion includes a state-of-the-art 286,000 sq. ft. production facility, a 28,000 sq. ft. greenhouse, and an additional 1,200 sq. ft. extraction laboratory. Upon completion, the New Facility is expected to be the largest purpose-built indoor cannabis production facility in the world.

TORONTO, May 5, 2017 /CNW/ - Cronos Group Inc.'s (TSXV:MJN) wholly owned licensed producer, the Peace Naturals Project Inc. ("Peace"), was notified on May 4, 2017 by Health Canada that upon testing a random cannabis leaf sample, trace levels of Piperonyl Butoxide...

TORONTO, May 2, 2017 /CNW/ - Cronos Group Inc. (TSXV:MJN) ("Cronos" or the "Company") is pleased to announce that following a comprehensive audit, the Company's wholly owned licensed producer ("LP"), the Peace Naturals Project Inc. ("Peace"), has been issued a Good...

TORONTO, ON--(Marketwired - May 01, 2017) Cronos Group Inc. (formerly PharmaCan Capital Corp.) (TSX VENTURE: MJN) ("Cronos" or the "Company") is pleased to report the financial results and accompanying management discussion and analysis for the year ending December...

TORONTO, ON--(Marketwired - April 24, 2017) Cronos Group Inc. (formerly PharmaCan Capital Corp.) (TSX VENTURE: MJN) ("Cronos", or the "Company") is providing an update on its investments in Whistler Medical Marijuana Corporation ("Whistler"), The Hydropothecary...

Cronos Group is pleased to announce that WMMC has been granted an affirmation letter from Health Canada regarding the company’s announced 65,000 square foot expansion in Pemberton, British Columbia.

Cronos Group is pleased to announce that it has closed its previously announced bought deal public offering.

TORONTO, Feb. 27, 2017 /CNW/ - Cronos Group Inc., formerly PharmaCan Capital Corp., (TSX VENTURE: MJN) ("Cronos Group" or "the Company"), is excited to announce the Company's recent recognition as the top performer in the 2017 TSX Venture 50, an award reserved for the...

        TORONTO, ONTARIO--(Marketwired - Feb. 14, 2017) - NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE:MJN) ("Cronos" or the "Company") is pleased...

        TORONTO, ON--(Marketwired - January 23, 2017) PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos" or the "Company"), seeks shareholder approval to formally change its name to "Cronos Group Inc." following the corporate...

In a landmark bill, members of Germany’s parliament voted unanimously to legalize the use of medical marijuana and have implemented a policy that will provide health insurance coverage for patients with an eligible prescription.

TORONTO, ON--(Marketwired - January 11, 2017) - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos" or the "Company"), is pleased to announce that the...

TORONTO, ON - (Marketwired - December 28, 2016) PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos" or "the Company"), is pleased to announce the execution of an exclusive supply agreement with German-based Pedanios GmbH ("Pedanios")...

The Cronos Group is pleased with and supportive of the recommendations provided in the report by the Task Force on Cannabis Legalization and Regulation.

Indigenous Roots will work cooperatively with First Nations towards building and operating licensed facilities and providing medical cannabis to patients.

TORONTO, ON –November 29, 2016 NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE PharmaCan Capital Corp., doing business as Cronos Group (TSXV:MJN) (“Cronos” or the “Company”) is pleased to provide the first operational update related to its...

TORONTO, ONTARIO--(Marketwired - Nov. 21, 2016) - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES PharmaCan Capital Corp. doing business as Cronos Group ("Cronos Group" or the "Company") (TSX VENTURE:MJN) announces it has granted...

TORONTO, ON--(Marketwired - October 24, 2016) - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos Group" or "the Company"), is pleased to announce...

TORONTO, ONTARIO--(Marketwired - October 11, 2016) - TORONTO, ON--(Marketwired - October 11, 2016) - PharmaCan Capital Corp., doing business as Cronos Group (TSX VENTURE: MJN) ("Cronos Group" or "the Company") is pleased to announce that its wholly owned subsidiary,...

PharmaCan Capital today announced a corporate rebranding to Cronos Group. This rebranding reflects the new strategic vision of the Company as Canada’s first bi-coastal licensed cannabis producer with interests in five Licensed Producers (“LPs”) and three license applicants.

PharmaCan has entered into a definitive Purchase Agreement to acquire approximately 17 acres of land adjacent to the existing campus of In the Zone Produce Ltd.

The acquisition of Peace Naturals immediately positions the Company as a dominant force in the Canadian cannabis market.

The proceeds of the Offering will be used for the financing by the Company of its acquisition of Peace Naturals Project Inc. and general corporate purposes.

The proceeds of the Offering will be used for the financing by the Company of its acquisition of Peace Naturals Project Inc.

PharmaCan is pleased to announce the closing of the first tranche (the “First Tranche”) of the previously announced non-brokered private placement.

PharmaCan Capital Corp. announces it has granted options to subscribe to an aggregate of 975,000 common shares in accordance with the Company’s stock option plan.

PharmaCan Capital Corp. is pleased to announce that it has entered into a share purchase agreement to acquire all of the shares of Peace Naturals Project Inc.

PharmaCan Capital Corp. is pleased to announce that Mr. Jason Adler will be joining the board of directors.

PharmaCan is pleased to announce the closing of second and final tranche of the previously announced non-brokered private placement.

PharmaCan Capital Corp. Lorne Gertner has announced his resignation as a director of PharmaCan effective May 19, 2016

PharmaCan announces closing of first tranche and is pleased to announce the appointment of Michael Gorenstein, effective immediately.

PharmaCan Capital Corp. is pleased to announce a non-brokered private placement offering (the “Offering”) to raise up to $5,000,000.

PharmaCan Capital Corp. has been served with a Statement of Claim filed by 2073056 Ontario Ltd in the Ontario Superior Court of Justice.

PharmaCan is pleased to announce that it has implemented a change to its Board of Directors reducing the number of serving Board members from seven to five.

PharmaCan has been advised that the proposed sale of the Barnes Family Trust’s shares in The Peace Naturals Project has been terminated.

ITZ has received approval from Health Canada for its application to amend its Marihuana for Medical Purposes Regulation (“MMPR”) license.

PharmaCan Capital Corp. announces that the proposed sale of the Barnes Family Trust’s shares in The Peace Naturals Project Inc., scheduled to close on December 11, 2015 did not close.

PharmaCan Capital Corp. announces that it has been provided with an update indicating the proposed sale of the Barnes Family Trust’s shares in Peace Naturals.

TORONTO, ON--(Marketwired - November 09, 2015) NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES PharmaCan Capital Corp. (TSX VENTURE: MJN) ("PharmaCan" or the "Company") announces the Board of Directors has adopted a Shareholders...

PharmaCan Capital Corp. announces that the Barnes Family Trust has provided an update that the proposed sale of its shares in Peace Naturals.

Notice that it will participate fully in the Share Purchase Agreement that the BFT entered into for the sale of all of their shares in Peace Naturals.

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES TORONTO, ON--(Marketwired - October 29, 2015) PharmaCan Capital Corp. (TSX VENTURE: MJN) ("PharmaCan" or the "Company") is pleased to announce the closing of additional tranches of...

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH UNITED STATES NEWSWIRE SERVICES TORONTO, ON--(Marketwired - October 15, 2015) PharmaCan Capital Corp. (TSX VENTURE: MJN) ("PharmaCan" or the "Company") announces the expiry unexercised of the previously disclosed...